BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandovici M, van der Geest N, van Sleen Y, Brouwer E. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open 2022;8:e001652. [PMID: 35149602 DOI: 10.1136/rmdopen-2021-001652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Stamatis P, Turesson C, Michailidou D, Mohammad AJ. Pathogenesis of giant cell arteritis with focus on cellular populations. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1058600] [Reference Citation Analysis]
2 Higashida-Konishi M, Akiyama M, Shimada T, Hama S, Oshige T, Izumi K, Oshima H, Okano Y. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy. Rheumatol Int 2022. [PMID: 36152056 DOI: 10.1007/s00296-022-05217-x] [Reference Citation Analysis]
3 van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, Heeringa P, Brouwer E, Jiemy WF. Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Front Med 2022;9:902155. [DOI: 10.3389/fmed.2022.902155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]